A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study.
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2013
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2012 Actual number of patient 49 added as reported by ClinicalTrials.gov. (NCT00206427)
- 06 Mar 2012 Actual end date (1 Feb 2012) added as reported by ClinicalTrials.gov. (NCT00206427).